Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs.

Fosun Pharma has paid $60 million for an option on AriBio’s late-phase Alzheimer’s disease program, securing the chance to ...

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...

Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 ...

Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather ...

A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the ...

A quantum tech firm that has collaborated with—and received investment from—Amgen is now planning to go public. | A quantum ...

Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a ...

Aardvark Therapeutics is planning to unblind data from its phase 3 Prader-Willi syndrome (PWS) program after the FDA put a ...

Three weeks after taking over as CEO of Lexicon Pharmaceuticals back in 2024, Michael Exton suggested the company close its ...

After a series of staff consolidation moves in recent weeks, Novartis is again trimming its ranks, albeit in what appears to ...

Takeda has ended development of its nausea and vomiting drug candidate for strategic reasons, continuing its multi-year ...